Biosimilars: Current state of the build up to series production;Biosimilars: Aktueller Stand der Serienreife

Zeitschrift fur Rheumatologie

Volumn 72, Issue 9, 2013, Pages 873-877

  Aringer, M ^a   Dorner T ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biologics; Drug approval; Drugs generic; Rituximab; Tumor necrosis factor alpha

Indexed keywords

BIOSIMILAR AGENT; GENERIC DRUG;

ARTICLE; BIOEQUIVALENCE; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; RHEUMATOLOGY; SOCIOECONOMICS;

BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUGS, GENERIC; EUROPEAN UNION;

EID: 84888645274     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-013-1140-y     Document Type: Article

References (15)

1. Feldmann M, Maini RN (2010) Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol 185(2):791-794
2. Tanaka T, Narazaki M, Kishimoto T (2011) Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 585(23):3699-3709
3. Edwards JC, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6(5):394-403
4. Zink A, Askling J, Dixon WG et al (2009) European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 68(8):1240-1246
5. Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975
6. Furst DE, Keystone EC, Braun J et al (2012) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 71(Suppl 2):i2-i45
7. Gossec L, Smolen JS, Gaujoux-Viala C et al (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71(1):4-12
8. Braun J, Berg R van den, Baraliakos X et al (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896-904
9. Dorner T, Strand V, Castaneda-Hernandez G et al (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72(3):322-328
10. Schoels M, Wong J, Scott DL et al (2010) Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69(6):995-1003
11. European Medicines Agency (o J) Questions and answers on generic medicines. (22-11-2012. Ref Type: Internet Communication)
12. European Medicines Agency (o J) Biosimilar medicines authorised viy the agency. (9-4-2013. Ref Type: Internet Communication)
13. Schiestl M, Stangler T, Torella C et al (2011) Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29(4):310-312
14. Yoo DH, Hrycaj P, Miranda P et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis
15. Park W, Hrycaj P, Jeka S et al (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis